New Policy on Cell and Gene Therapy: How Can International Patients Seek Treatment in Compliance?

Introduction

Cell and gene therapy (CGT) is moving from the laboratory to clinical practice, with a surge in global demand for therapies such as CAR-T and gene editing. In 2023, China's National Medical Products Administration (NMPA) issued a series of documents, including the "Guidelines for Quality Management of Cell Therapy Product Manufacturing," further standardizing the clinical application of CGT. For international patients, this means a clearer compliant pathway for medical treatment, but it also involves complex approvals and procedures. Based on the latest policies, this article provides a practical guide for seeking treatment.

Core of the New Policy: A Clearer Regulatory Framework

From 2023 to 2024, China's CGT regulation entered a new phase: the NMPA manages cell therapy products as drugs, requiring dual filing of clinical trials with both the NMPA and the National Health Commission (NHC). Meanwhile, the NHC issued the "Guidelines for Somatic Cell Clinical Research," distinguishing between "research" and "therapeutic" applications. Key changes include:

Qualification Threshold: Hospitals conducting CGT clinical trials must have Grade III Level A qualifications and possess GMP-grade cell preparation laboratories.

Approval Process: Patients must undergo dual review by the hospital's ethics committee and academic committee. International patients are additionally required to submit proof of foreign identity and referral materials from their home country.

Exemption Clauses: For patients with rare diseases or those in advanced stages of life, a fast-track "compassionate use" pathway may be applied for, but sufficient medical evidence must be provided.

These policies significantly enhance the standardization and traceability of treatment, but also require patients to be more thoroughly prepared.

Comparison of China-US Regulations: Differences Everywhere

Using the US FDA and EU EMA as references, China's new policy shows significant differences in the following aspects:

Approval Duration: The US FDA's RMAT designation can accelerate approval, while China emphasizes the "dual filing" process, typically taking 3-6 months. International patients should allow for a longer waiting period.

Cost Payment: The cost of CGT treatment in the US ranges from approximately $373,000 to $475,000, while the average cost in China is about 2-3 million RMB. However, most programs require self-payment and are not covered by medical insurance.

Data Mutual Recognition: China has not fully accepted overseas clinical data, so international patients may need to undergo additional repeat tests (such as genetic sequencing, imaging), which increases both costs and timelines.

Understanding these differences helps you plan your budget and time reasonably.

Treatment Process for International Patients: A Four-Step Approach

Step 1: Initial Consultation and Eligibility Assessment

Submit your medical records summary, diagnostic reports, and treatment history through Contact Us or a medical intermediary. The hospital will conduct a preliminary assessment to determine if you meet the indications for CGT (e.g., hematologic malignancies, genetic diseases). This phase typically takes 2-4 weeks, and it is recommended to prepare English translations.

Step 2: Ethics Review and Material Preparation

The hospital will initiate an ethics review for you. You will need to provide:

A valid passport and visa (a medical visa requires a certificate from the designated hospital)

A referral letter from your primary physician in your home country (notarized in English)

Detailed medical history records and laboratory test results

Informed consent form (translation required, and you must undergo an interview with the ethics committee)

To expedite the process, it is recommended to use the Cost Estimator tool to get an initial understanding of costs and prepare proof of funds.

Step 3: Treatment Implementation and Inpatient Management

After approval, you will undergo cell collection, preparation, and infusion. The hospitalization period is typically 4-6 weeks, during which virological and immunological monitoring is required. Chinese hospitals generally offer international wards, but it is advisable to confirm whether an English-speaking medical coordinator is available.

Step 4: Long-term Follow-up and Remote Management

Follow-up after CGT treatment is crucial. Some hospitals offer remote follow-up services, but international patients need to return to China for re-examination every 3-6 months for at least 2 years. Keep all treatment records for subsequent management in your home country.

Risks and Precautions: Details That Cannot Be Overlooked

Policy Change Risk: Regulatory policies may change. It is recommended to sign a "policy change response clause" with the hospital before treatment, clarifying the refund mechanism if approval fails.

Medical Liability: The medical dispute litigation process in China differs significantly from that in your home country. When purchasing international medical insurance, confirm whether it covers CGT treatment within China.

Cultural Differences: Some treatments (e.g., allogeneic cells) may involve donor sources, so it is important to understand ethical sensitivities in advance.

Recommendations for International Patients

Cell and gene therapy is highly individualized cutting-edge medicine, and compliance is the prerequisite for safety. We recommend:

Plan 6 Months in Advance: From consultation to treatment, allow at least half a year to avoid missing the optimal treatment window due to approval delays.

Seek Professional Support: Choose a reputable hospital with experience in serving international patients, or obtain one-on-one guidance through the MeiJiaKang Platform to ensure complete documentation.

Keep Written Records: Retain all communication, approvals, and payment receipts for rights protection and subsequent treatment.

Consider Long-term Costs: In addition to treatment fees, factor in travel, accommodation, and follow-up costs, increasing the total budget by 20%.

CGT brings hope, but rational planning is what turns hope into reality. If you have more questions, feel free to Contact Us, and our medical team will provide professional advice.